查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
Aflibercept Biosimilars的全球市場，實際成果與預測(2018年～2029年)
市場調查報告書
商品編碼
1389914

Aflibercept Biosimilars的全球市場，實際成果與預測(2018年～2029年)

Global Aflibercept Biosimilars Market Report, History and Forecast 2018-2029
出版日期: | 出版商: QYResearch | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球Aflibercept Biosimilars的市場規模將從2022年的98億6,964萬美元到2029年達到103億9,994萬美元，2023年～2029年的預測期間將以年複合成長率1.41％的速度成長。

北美市場將從2022年的76億3,971萬美元到2029年達到84億5,936萬美元，預測期間的年複合成長率是1.74％。

亞太地區市場預計從2022年的4億3,624萬美元到2029年成為3億8,496萬美元，預測期間的年複合成長率是-2.22％。

歐洲市場將從2022年的17億5,349萬美元到2029年達到15億3,767萬美元，預測期間的年複合成長率是0.78％。

本報告提供全球Aflibercept Biosimilars市場相關調查分析，提供各地區市場規模與預測，市場動態，競爭情形等資訊。

目錄

第1章 Aflibercept Biosimilars市場概要

  • Aflibercept Biosimilars產品概要
  • Aflibercept Biosimilars市場:各類型
    • 2mg
    • 8mg
  • 全球Aflibercept Biosimilars的市場規模:各類型
    • 全球Aflibercept Biosimilars的市場規模概要:各類型(2018年～2029年)
    • 全球Aflibercept Biosimilars的市場規模的實際成果的檢討:各類型(2018年～2023年)
    • 全球Aflibercept Biosimilars的市場規模的預測:各類型(2024年～2029年)
  • 主要地區的市場規模:各類型
    • 北美的Aflibercept Biosimilars的銷售額的明細:各類型(2018年～2023年)
    • 歐洲的Aflibercept Biosimilars的銷售額的明細:各類型(2018年～2023年)
    • 亞太地區的Aflibercept Biosimilars的銷售額的明細:各類型(2018年～2023年)
    • 南美的Aflibercept Biosimilars的銷售額的明細:各類型(2018年～2023年)
    • 中東·非洲的Aflibercept Biosimilars的銷售額的明細:各類型(2018年～2023年)

第2章 Aflibercept Biosimilars市場競爭:各企業

  • 全球主要企業:Aflibercept Biosimilars的各銷售額(2018年～2023年)
  • 全球主要企業:Aflibercept Biosimilars的各銷售額(2018年～2023年)
  • 全球主要企業:Aflibercept Biosimilars的各價格(2018年～2023年)
  • 全球主要製造商Aflibercept Biosimilars製造地的分佈，銷售區域，產品類型
  • Aflibercept Biosimilars市場競爭形勢和趨勢
    • Aflibercept Biosimilars的市場集中度(2018年～2023年)
    • 全球最大的廠商(2022年的Aflibercept Biosimilars的銷售額和收益)
  • 全球主要製造商:各類型企業(Tier 1·Tier 2·Tier 3)(2022年的Aflibercept Biosimilars的收益為主)
  • 主要製造商的Aflibercept Biosimilars市場進入日
  • 主要製造商所提供的Aflibercept Biosimilars產品
  • 合併和收購，擴大

第3章 Aflibercept Biosimilars的現況與展望:各地區

  • 全球Aflibercept Biosimilars的市場規模和年複合成長率:各地區(2018年·2022年·2029年)
  • 全球Aflibercept Biosimilars的市場規模的實際成果:各地區
    • 全球Aflibercept Biosimilars的銷售額數量:各地區(2018年～2023年)
    • 全球Aflibercept Biosimilars的銷售額額:各地區(2018年～2023年)
    • 全球Aflibercept Biosimilars的銷售額(數量和金額)，價格，毛利(2018年～2023年)
  • 全球Aflibercept Biosimilars的市場規模的預測:各地區
    • 全球Aflibercept Biosimilars的銷售額數量:各地區(2024年～2029年)
    • 全球Aflibercept Biosimilars的銷售額額:各地區(2024年～2029年)
    • 全球Aflibercept Biosimilars的銷售額(數量和金額)，價格，毛利(2024年～2029年)

第4章 Aflibercept Biosimilars:各用途

  • Aflibercept Biosimilars市場:各用途
    • 醫院
    • 診療所
    • 其他
  • 全球Aflibercept Biosimilars的市場規模:各用途
    • 全球Aflibercept Biosimilars的市場規模概要:各用途(2018年～2029年)
    • 全球Aflibercept Biosimilars的市場規模的實際成果的檢討:各用途(2018年～2023年)
    • 全球Aflibercept Biosimilars的市場規模的預測:各用途(2024年～2029年)
  • 主要地區的市場規模:各用途
    • 北美的Aflibercept Biosimilars的銷售額的明細:各用途(2018年～2023年)
    • 歐洲的Aflibercept Biosimilars的銷售額的明細:各用途(2018年～2023年)
    • 亞太地區的Aflibercept Biosimilars的銷售額的明細:各用途(2018年～2023年)
    • 南美的Aflibercept Biosimilars的銷售額的明細:各用途(2018年～2023年)
    • 中東·非洲的Aflibercept Biosimilars的銷售額的明細:各用途(2018年～2023年)

第5章 北美的Aflibercept Biosimilars:各國

  • 北美的Aflibercept Biosimilars的市場規模的實際成果:各國
  • 北美的Aflibercept Biosimilars的市場規模的預測:各國

第6章 歐洲的Aflibercept Biosimilars:各國

  • 歐洲的Aflibercept Biosimilars的市場規模的實際成果:各國
  • 歐洲的Aflibercept Biosimilars的市場規模的預測:各國

第7章 亞太地區的Aflibercept Biosimilars:各地區

  • 亞太地區的Aflibercept Biosimilars的市場規模的實際成果:各地區
  • 亞太地區的Aflibercept Biosimilars的市場規模的預測:各地區

第8章 南美的Aflibercept Biosimilars:各國

  • 南美的Aflibercept Biosimilars的市場規模的實際成果:各國
  • 南美的Aflibercept Biosimilars的市場規模的預測:各國

第9章 中東·非洲的Aflibercept Biosimilars:各國

  • 中東·非洲的Aflibercept Biosimilars的市場規模的實際成果:各國
  • 中東·非洲的Aflibercept Biosimilars的市場規模的預測:各國

第10章 企業簡介

  • Regeneron Pharmaceuticals
  • Bayer HealthCare
  • Kanghong Pharma
  • Biocon
  • AbbVie
  • Roche
  • Novartis
  • QILU Pharmaceutical
  • Regenxbio
  • Samsung Bioepis
  • Amgen
  • Formycon

第11章 機會，課題，風險，影響要素的分析

  • Aflibercept Biosimilars的產業鏈分析
  • Aflibercept Biosimilars的市場動態
    • Aflibercept Biosimilars產業趨勢
    • Aflibercept Biosimilars市場促進因素
    • Aflibercept Biosimilars市場課題
    • Aflibercept Biosimilars市場阻礙因素

第12章 行銷策略的分析，銷售商

  • 銷售管道
  • Aflibercept Biosimilars的銷售商
  • Aflibercept Biosimilars的下遊客戶

第13章 調查結果與結論

第14章 附錄

The global market for Aflibercept Biosimilars was estimated at US$ 9869.64 million in the year 2022, is projected to reach a revised size of US$ 10399.94 million by 2029, growing at a CAGR of 1.41 % during the forecast period 2023-2029.

North American market for Aflibercept Biosimilars was valued at $ 7639.71 million in 2022 and will reach $ 8459.36 million by 2029, at a CAGR of 1.74 % during the forecast period of 2023 through 2029.

Asia-Pacific market for Aflibercept Biosimilars was valued at $ 436.24million in 2022 and will reach $ 384.96 million by 2029, at a CAGR of -2.22% during the forecast period of 2023 through 2029.

Europe market for Aflibercept Biosimilars was valued at $ 1753.49 million in 2022 and will reach $ 1537.67 million by 2029, at a CAGR of 0.78% during the forecast period of 2023 through 2029.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Aflibercept Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Aflibercept Biosimilars.

The Aflibercept Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Aflibercept Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aflibercept Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

Market Segmentation

This report covers the Aflibercept Biosimilars segments by manufacturers, by Type, by Application, by region and country, and provides market size (value, volume and average price) and CAGR for the history and forecast period (2018-2022, 2023-2029), considering 2022 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

By Company

  • Regeneron Pharmaceuticals
  • Bayer HealthCare
  • Kanghong Pharma
  • Biocon

Segment by Type

  • 2mg
  • 8mg

Segment by Application

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Southeast Asia
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
  • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE

Core Chapters

Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Chapter Two: Detailed analysis of Aflibercept Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter Three: Sales, revenue of Aflibercept Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.

Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter Twelve: Analysis of sales channel, distributors and customers.

Chapter Thirteen: Research Findings and Conclusion.

Table of Contents

1 Aflibercept Biosimilars Market Overview

  • 1.1 Aflibercept Biosimilars Product Overview
  • 1.2 Aflibercept Biosimilars Market by Type
    • 1.2.1 2mg
    • 1.2.2 8mg
  • 1.3 Global Aflibercept Biosimilars Market Size by Type
    • 1.3.1 Global Aflibercept Biosimilars Market Size Overview by Type (2018-2029)
    • 1.3.2 Global Aflibercept Biosimilars Historic Market Size Review by Type (2018-2023)
    • 1.3.3 Global Aflibercept Biosimilars Forecasted Market Size by Type (2024-2029)
  • 1.4 Key Regions Market Size by Type
    • 1.4.1 North America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • 1.4.2 Europe Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • 1.4.3 Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • 1.4.4 Latin America Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)
    • 1.4.5 Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Type (2018-2023)

2 Aflibercept Biosimilars Market Competition by Company

  • 2.1 Global Top Players by Aflibercept Biosimilars Sales (2018-2023)
  • 2.2 Global Top Players by Aflibercept Biosimilars Revenue (2018-2023)
  • 2.3 Global Top Players by Aflibercept Biosimilars Price (2018-2023)
  • 2.4 Global Top Manufacturers Aflibercept Biosimilars Manufacturing Base Distribution, Sales Area, Product Type
  • 2.5 Aflibercept Biosimilars Market Competitive Situation and Trends
    • 2.5.1 Aflibercept Biosimilars Market Concentration Rate (2018-2023)
    • 2.5.2 Global Largest Manufacturers by Aflibercept Biosimilars Sales and Revenue in 2022
  • 2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Aflibercept Biosimilars as of 2022)
  • 2.7 Date of Key Manufacturers Enter into Aflibercept Biosimilars Market
  • 2.8 Key Manufacturers Aflibercept Biosimilars Product Offered
  • 2.9 Mergers & Acquisitions, Expansion

3 Aflibercept Biosimilars Status and Outlook by Region

  • 3.1 Global Aflibercept Biosimilars Market Size and CAGR by Region: 2018 VS 2022 VS 2029
  • 3.2 Global Aflibercept Biosimilars Historic Market Size by Region
    • 3.2.1 Global Aflibercept Biosimilars Sales in Volume by Region (2018-2023)
    • 3.2.2 Global Aflibercept Biosimilars Sales in Value by Region (2018-2023)
    • 3.2.3 Global Aflibercept Biosimilars Sales (Volume & Value), Price and Gross Margin (2018-2023)
  • 3.3 Global Aflibercept Biosimilars Forecasted Market Size by Region
    • 3.3.1 Global Aflibercept Biosimilars Sales in Volume by Region (2024-2029)
    • 3.3.2 Global Aflibercept Biosimilars Sales in Value by Region (2024-2029)
    • 3.3.3 Global Aflibercept Biosimilars Sales (Volume & Value), Price and Gross Margin (2024-2029)

4 Aflibercept Biosimilars by Application

  • 4.1 Aflibercept Biosimilars Market by Application
    • 4.1.1 Hospitals
    • 4.1.2 Clinics
    • 4.1.3 Others
  • 4.2 Global Aflibercept Biosimilars Market Size by Application
    • 4.2.1 Global Aflibercept Biosimilars Market Size Overview by Application (2018-2029)
    • 4.2.2 Global Aflibercept Biosimilars Historic Market Size Review by Application (2018-2023)
    • 4.2.3 Global Aflibercept Biosimilars Forecasted Market Size by Application (2024-2029)
  • 4.3 Key Regions Market Size by Application
    • 4.3.1 North America Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
    • 4.3.2 Europe Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
    • 4.3.3 Asia-Pacific Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
    • 4.3.4 Latin America Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)
    • 4.3.5 Middle East and Africa Aflibercept Biosimilars Sales Breakdown by Application (2018-2023)

5 North America Aflibercept Biosimilars by Country

  • 5.1 North America Aflibercept Biosimilars Historic Market Size by Country
    • 5.1.1 North America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
    • 5.1.2 North America Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
    • 5.1.3 North America Aflibercept Biosimilars Sales in Value by Country (2018-2023)
  • 5.2 North America Aflibercept Biosimilars Forecasted Market Size by Country
    • 5.2.1 North America Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
    • 5.2.2 North America Aflibercept Biosimilars Sales in Value by Country (2024-2029)

6 Europe Aflibercept Biosimilars by Country

  • 6.1 Europe Aflibercept Biosimilars Historic Market Size by Country
    • 6.1.1 Europe Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
    • 6.1.2 Europe Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
    • 6.1.3 Europe Aflibercept Biosimilars Sales in Value by Country (2018-2023)
  • 6.2 Europe Aflibercept Biosimilars Forecasted Market Size by Country
    • 6.2.1 Europe Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
    • 6.2.2 Europe Aflibercept Biosimilars Sales in Value by Country (2024-2029)

7 Asia-Pacific Aflibercept Biosimilars by Region

  • 7.1 Asia-Pacific Aflibercept Biosimilars Historic Market Size by Region
    • 7.1.1 Asia-Pacific Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
    • 7.1.2 Asia-Pacific Aflibercept Biosimilars Sales in Volume by Region (2018-2023)
    • 7.1.3 Asia-Pacific Aflibercept Biosimilars Sales in Value by Region (2018-2023)
  • 7.2 Asia-Pacific Aflibercept Biosimilars Forecasted Market Size by Region
    • 7.2.1 Asia-Pacific Aflibercept Biosimilars Sales in Volume by Region (2024-2029)
    • 7.2.2 Asia-Pacific Aflibercept Biosimilars Sales in Value by Region (2024-2029)

8 Latin America Aflibercept Biosimilars by Country

  • 8.1 Latin America Aflibercept Biosimilars Historic Market Size by Country
    • 8.1.1 Latin America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
    • 8.1.2 Latin America Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
    • 8.1.3 Latin America Aflibercept Biosimilars Sales in Value by Country (2018-2023)
  • 8.2 Latin America Aflibercept Biosimilars Forecasted Market Size by Country
    • 8.2.1 Latin America Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
    • 8.2.2 Latin America Aflibercept Biosimilars Sales in Value by Country (2024-2029)

9 Middle East and Africa Aflibercept Biosimilars by Country

  • 9.1 Middle East and Africa Aflibercept Biosimilars Historic Market Size by Country
    • 9.1.1 Middle East and Africa Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
    • 9.1.2 Middle East and Africa Aflibercept Biosimilars Sales in Volume by Country (2018-2023)
    • 9.1.3 Middle East and Africa Aflibercept Biosimilars Sales in Value by Country (2018-2023)
  • 9.2 Middle East and Africa Aflibercept Biosimilars Forecasted Market Size by Country
    • 9.2.1 Middle East and Africa Aflibercept Biosimilars Sales in Volume by Country (2024-2029)
    • 9.2.2 Middle East and Africa Aflibercept Biosimilars Sales in Value by Country (2024-2029)

10 Company Profiles

  • 10.1 Regeneron Pharmaceuticals
    • 10.1.1 Regeneron Pharmaceuticals Company Information
    • 10.1.2 Regeneron Pharmaceuticals Introduction and Business Overview
    • 10.1.3 Regeneron Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.1.4 Regeneron Pharmaceuticals Aflibercept Biosimilars Products Offered
    • 10.1.5 Regeneron Pharmaceuticals Recent Development
  • 10.2 Bayer HealthCare
    • 10.2.1 Bayer HealthCare Company Information
    • 10.2.2 Bayer HealthCare Introduction and Business Overview
    • 10.2.3 Bayer HealthCare Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.2.4 Bayer HealthCare Aflibercept Biosimilars Products Offered
    • 10.2.5 Bayer HealthCare Recent Development
  • 10.3 Kanghong Pharma
    • 10.3.1 Kanghong Pharma Company Information
    • 10.3.2 Kanghong Pharma Introduction and Business Overview
    • 10.3.3 Kanghong Pharma Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
    • 10.3.4 Kanghong Pharma Aflibercept Biosimilars Products Offered
    • 10.3.5 Kanghong Pharma Recent Development
  • 10.4 Biocon
    • 10.4.1 Biocon Company Information
    • 10.4.2 Biocon Introduction and Business Overview
    • 10.4.3 Biocon Aflibercept Biosimilars Products Offered
    • 10.4.4 Biocon Recent Development
  • 10.5 AbbVie
    • 10.5.1 AbbVie Company Information
    • 10.5.2 AbbVie Introduction and Business Overview
    • 10.5.3 AbbVie Aflibercept Biosimilars Products Offered
    • 10.5.4 AbbVie Recent Development
  • 10.6 Roche
    • 10.6.1 Roche Company Information
    • 10.6.2 Roche Introduction and Business Overview
    • 10.6.3 Roche Aflibercept Biosimilars Products Offered
    • 10.6.4 Roche Recent Development
  • 10.7 Novartis
    • 10.7.1 Novartis Company Information
    • 10.7.2 Novartis Introduction and Business Overview
    • 10.7.3 Novartis Aflibercept Biosimilars Products Offered
    • 10.7.4 Novartis Recent Development
  • 10.8 QILU Pharmaceutical
    • 10.8.1 QILU Pharmaceutical Company Information
    • 10.8.2 QILU Pharmaceutical Introduction and Business Overview
    • 10.8.3 QILU Pharmaceutical Aflibercept Biosimilars Products Offered
    • 10.8.4 QILU Pharmaceutical Recent Development
  • 10.9 Regenxbio
    • 10.9.1 Regenxbio Company Information
    • 10.9.2 Regenxbio Introduction and Business Overview
    • 10.9.3 Regenxbio Aflibercept Biosimilars Products Offered
    • 10.9.4 Regenxbio Recent Development
  • 10.10 Samsung Bioepis
    • 10.10.1 Samsung Bioepis Company Information
    • 10.10.2 Samsung Bioepis Introduction and Business Overview
    • 10.10.3 Samsung Bioepis Aflibercept Biosimilars Products Offered
    • 10.10.4 Samsung Bioepis Recent Development
  • 10.11 Amgen
    • 10.11.1 Amgen Company Information
    • 10.11.2 Amgen Introduction and Business Overview
    • 10.11.3 Amgen Aflibercept Biosimilars Products Offered
  • 10.12 Formycon
    • 10.12.1 Formycon Company Information
    • 10.12.2 Formycon Introduction and Business Overview
    • 10.12.3 Formycon Aflibercept Biosimilars Products Offered
    • 10.12.4 Formycon Recent Development

11 Opportunities, Challenges, Risks and Influences Factors Analysis

  • 11.1 Aflibercept Biosimilars Industrial Chain Analysis
  • 11.2 Aflibercept Biosimilars Market Dynamics
    • 11.2.1 Aflibercept Biosimilars Industry Trends
    • 11.2.2 Aflibercept Biosimilars Market Drivers
    • 11.2.3 Aflibercept Biosimilars Market Challenges
    • 11.2.4 Aflibercept Biosimilars Market Restraints

12 Marketing Strategy Analysis, Distributors

  • 12.1 Sales Channel
  • 12.2 Aflibercept Biosimilars Distributors
  • 12.3 Aflibercept Biosimilars Downstream Customers

13 Research Findings and Conclusion

14 Appendix

  • 14.1 Research Methodology
    • 14.1.1 Methodology/Research Approach
    • 14.1.2 Data Source
  • 14.2 Author Details
  • 14.3 Disclaimer

List of Tables

  • Table 1. Major Company of 2mg
  • Table 2. Major Company of 8mg
  • Table 3. Global Aflibercept Biosimilars Sales by Type: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 4. Global Aflibercept Biosimilars Sales by Type (2018-2023) & (K Units)
  • Table 5. Global Aflibercept Biosimilars Sales Market Share in Volume by Type (2018-2023)
  • Table 6. Global Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 7. Global Aflibercept Biosimilars Sales Market Share in Value by Type (2018-2023)
  • Table 8. Global Aflibercept Biosimilars Price by Type (2018-2023) & (US$/Unit)
  • Table 9. Global Aflibercept Biosimilars Sales by Type (2024-2029) & (K Units)
  • Table 10. Global Aflibercept Biosimilars Sales Market Share in Volume by Type (2024-2029)
  • Table 11. Global Aflibercept Biosimilars Sales by Type (2024-2029) & (US$ Million)
  • Table 12. Global Aflibercept Biosimilars Sales Market Share in Value by Type (2024-2029)
  • Table 13. Global Aflibercept Biosimilars Price by Type (2024-2029) & (US$/Unit)
  • Table 14. North America Aflibercept Biosimilars Sales by Type (2018-2023) & (K Units)
  • Table 15. North America Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 16. Europe Aflibercept Biosimilars Sales (K Units) by Type (2018-2023)
  • Table 17. Europe Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 18. Asia-Pacific Aflibercept Biosimilars Sales (K Units) by Type (2018-2023)
  • Table 19. Asia-Pacific Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 20. Latin America Aflibercept Biosimilars Sales (K Units) by Type (2018-2023)
  • Table 21. Latin America Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 22. Middle East and Africa Aflibercept Biosimilars Sales (K Units) by Type (2018-2023)
  • Table 23. Middle East and Africa Aflibercept Biosimilars Sales by Type (2018-2023) & (US$ Million)
  • Table 24. Global Aflibercept Biosimilars Sales by Company (2018-2023) & (K Units)
  • Table 25. Global Aflibercept Biosimilars Sales Share by Company (2018-2023)
  • Table 26. Global Aflibercept Biosimilars Revenue by Company (2018-2023) & (US$ Million)
  • Table 27. Global Aflibercept Biosimilars Revenue Share by Company (2018-2023)
  • Table 28. Global Market Aflibercept Biosimilars Price by Company (2018-2023) & (US$/Unit)
  • Table 29. Global Aflibercept Biosimilars Top Manufacturers Manufacturing Base Distribution and Sales Area
  • Table 30. Global Aflibercept Biosimilars Manufacturers Market Concentration Ratio
  • Table 31. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Aflibercept Biosimilars as of 2022)
  • Table 32. Date of Key Manufacturers Enter into Aflibercept Biosimilars Market
  • Table 33. Key Manufacturers Aflibercept Biosimilars Product Type
  • Table 34. Mergers & Acquisitions, Expansion Plans
  • Table 35. Global Aflibercept Biosimilars Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
  • Table 36. Global Aflibercept Biosimilars Sales by Region (2018-2023) & (K Units)
  • Table 37. Global Aflibercept Biosimilars Sales Market Share in Volume by Region (2018-2023)
  • Table 38. Global Aflibercept Biosimilars Sales by Region (2018-2023) & (US$ Million)
  • Table 39. Global Aflibercept Biosimilars Sales Market Share in Value by Region (2018-2023)
  • Table 40. Global Aflibercept Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 41. Global Aflibercept Biosimilars Sales by Region (2024-2029) & (K Units)
  • Table 42. Global Aflibercept Biosimilars Sales Market Share in Volume by Region (2024-2029)
  • Table 43. Global Aflibercept Biosimilars Sales by Region (2024-2029) & (US$ Million)
  • Table 44. Global Aflibercept Biosimilars Sales Market Share in Value by Region (2024-2029)
  • Table 45. Global Aflibercept Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
  • Table 46. Global Aflibercept Biosimilars Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 47. Global Aflibercept Biosimilars Sales by Application (2018-2023) & (K Units)
  • Table 48. Global Aflibercept Biosimilars Sales Market Share in Volume by Application (2018-2023)
  • Table 49. Global Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 50. Global Aflibercept Biosimilars Sales Market Share in Value by Application (2018-2023)
  • Table 51. Global Aflibercept Biosimilars Price by Application (2018-2023) & (US$/Unit)
  • Table 52. Global Aflibercept Biosimilars Sales by Application (2024-2029) & (K Units)
  • Table 53. Global Aflibercept Biosimilars Sales Market Share in Volume by Application (2024-2029)
  • Table 54. Global Aflibercept Biosimilars Sales by Application (2024-2029) & (US$ Million)
  • Table 55. Global Aflibercept Biosimilars Sales Market Share in Value by Application (2024-2029)
  • Table 56. Global Aflibercept Biosimilars Price by Application (2024-2029) & (US$/Unit)
  • Table 57. North America Aflibercept Biosimilars Sales by Application (2018-2023) & (K Units)
  • Table 58. North America Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 59. Europe Aflibercept Biosimilars Sales (K Units) by Application (2018-2023)
  • Table 60. Europe Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 61. Asia-Pacific Aflibercept Biosimilars Sales (K Units) by Application (2018-2023)
  • Table 62. Asia-Pacific Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 63. Latin America Aflibercept Biosimilars Sales (K Units) by Application (2018-2023)
  • Table 64. Latin America Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 65. Middle East and Africa Aflibercept Biosimilars Sales (K Units) by Application (2018-2023)
  • Table 66. Middle East and Africa Aflibercept Biosimilars Sales by Application (2018-2023) & (US$ Million)
  • Table 67. North America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
  • Table 68. North America Aflibercept Biosimilars Sales by Country (2018-2023) & (K Units)
  • Table 69. North America Aflibercept Biosimilars Sales Market Share in Volume by Country (2018-2023)
  • Table 70. North America Aflibercept Biosimilars Sales by Country (2018-2023) & (US$ Million)
  • Table 71. North America Aflibercept Biosimilars Sales Market Share in Value by Country (2018-2023)
  • Table 72. North America Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
  • Table 73. North America Aflibercept Biosimilars Sales Market Share in Volume by Country (2024-2029)
  • Table 74. North America Aflibercept Biosimilars Sales by Country (2024-2029) & (US$ Million)
  • Table 75. North America Aflibercept Biosimilars Sales Market Share in Value by Country (2024-2029)
  • Table 76. Europe Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
  • Table 77. Europe Aflibercept Biosimilars Sales by Country (2018-2023) & (K Units)
  • Table 78. Europe Aflibercept Biosimilars Sales Market Share in Volume by Country (2018-2023)
  • Table 79. Europe Aflibercept Biosimilars Sales by Country (2018-2023) & (US$ Million)
  • Table 80. Europe Aflibercept Biosimilars Sales Market Share in Value by Country (2018-2023)
  • Table 81. Europe Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
  • Table 82. Europe Aflibercept Biosimilars Sales Market Share in Volume by Country (2024-2029)
  • Table 83. Europe Aflibercept Biosimilars Sales by Country (2024-2029) & (US$ Million)
  • Table 84. Europe Aflibercept Biosimilars Sales Market Share in Value by Country (2024-2029)
  • Table 85. Asia-Pacific Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
  • Table 86. Asia-Pacific Aflibercept Biosimilars Sales by Region (2018-2023) & (K Units)
  • Table 87. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Volume by Region (2018-2023)
  • Table 88. Asia-Pacific Aflibercept Biosimilars Sales by Region (2018-2023) & (US$ Million)
  • Table 89. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Value by Region (2018-2023)
  • Table 90. Asia-Pacific Aflibercept Biosimilars Sales by Region (2024-2029) & (K Units)
  • Table 91. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Volume by Region (2024-2029)
  • Table 92. Asia-Pacific Aflibercept Biosimilars Sales by Region (2024-2029) & (US$ Million)
  • Table 93. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Value by Region (2024-2029)
  • Table 94. Latin America Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
  • Table 95. Latin America Aflibercept Biosimilars Sales by Country (2018-2023) & (K Units)
  • Table 96. Latin America Aflibercept Biosimilars Sales Market Share in Volume by Country (2018-2023)
  • Table 97. Latin America Aflibercept Biosimilars Sales by Country (2018-2023) & (US$ Million)
  • Table 98. Latin America Aflibercept Biosimilars Sales Market Share in Value by Country (2018-2023)
  • Table 99. Latin America Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
  • Table 100. Latin America Aflibercept Biosimilars Sales Market Share in Volume by Country (2024-2029)
  • Table 101. Latin America Aflibercept Biosimilars Sales by Country (2024-2029) & (US$ Million)
  • Table 102. Latin America Aflibercept Biosimilars Sales Market Share in Value by Country (2024-2029)
  • Table 103. Middle East and Africa Aflibercept Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
  • Table 104. Middle East and Africa Aflibercept Biosimilars Sales by Country (2018-2023) & (K Units)
  • Table 105. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Volume by Country (2018-2023)
  • Table 106. Middle East and Africa Aflibercept Biosimilars Sales by Country (2018-2023) & (US$ Million)
  • Table 107. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Value by Country (2018-2023)
  • Table 108. Middle East and Africa Aflibercept Biosimilars Sales by Country (2024-2029) & (K Units)
  • Table 109. Middle East and Africa Aflibercept Biosimilars Sales Market Share by Country (2024-2029)
  • Table 110. Middle East and Africa Aflibercept Biosimilars Sales by Country (2024-2029) & (US$ Million)
  • Table 111. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Value by Country (2024-2029)
  • Table 112. Regeneron Pharmaceuticals Company Information
  • Table 113. Regeneron Pharmaceuticals Introduction and Business Overview
  • Table 114. Regeneron Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 115. Regeneron Pharmaceuticals Aflibercept Biosimilars Product
  • Table 116. Regeneron Pharmaceuticals Recent Development
  • Table 117. Bayer HealthCare Company Information
  • Table 118. Bayer HealthCare Introduction and Business Overview
  • Table 119. Bayer HealthCare Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 120. Bayer HealthCare Aflibercept Biosimilars Product
  • Table 121. Bayer HealthCare Recent Development
  • Table 122. Kanghong Pharma Company Information
  • Table 123. Kanghong Pharma Introduction and Business Overview
  • Table 124. Kanghong Pharma Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
  • Table 125. Kanghong Pharma Aflibercept Biosimilars Product
  • Table 126. Kanghong Pharma Recent Development
  • Table 127. Biocon Company Information
  • Table 128. Biocon Introduction and Business Overview
  • Table 129. Biocon Aflibercept Biosimilars Product
  • Table 130. Biocon Recent Development
  • Table 131. AbbVie Company Information
  • Table 132. AbbVie Introduction and Business Overview
  • Table 133. AbbVie Aflibercept Biosimilars Product
  • Table 134. AbbVie Recent Development
  • Table 135. Roche Company Information
  • Table 136. Roche Introduction and Business Overview
  • Table 137. Roche Aflibercept Biosimilars Product
  • Table 138. Roche Recent Development
  • Table 139. Novartis Company Information
  • Table 140. Novartis Introduction and Business Overview
  • Table 141. Novartis Aflibercept Biosimilars Product
  • Table 142. Novartis Recent Development
  • Table 143. QILU Pharmaceutical Company Information
  • Table 144. QILU Pharmaceutical Introduction and Business Overview
  • Table 145. QILU Pharmaceutical Aflibercept Biosimilars Product
  • Table 146. QILU Pharmaceutical Recent Development
  • Table 147. Regenxbio Company Information
  • Table 148. Regenxbio Introduction and Business Overview
  • Table 149. Regenxbio Aflibercept Biosimilars Product
  • Table 150. Regenxbio Recent Development
  • Table 151. Samsung Bioepis Company Information
  • Table 152. Samsung Bioepis Introduction and Business Overview
  • Table 153. Samsung Bioepis Aflibercept Biosimilars Product
  • Table 154. Samsung Bioepis Recent Development
  • Table 155. Amgen Company Information
  • Table 156. Amgen Introduction and Business Overview
  • Table 157. Amgen Aflibercept Biosimilars Product
  • Table 158. Formycon Company Information
  • Table 159. Formycon Introduction and Business Overview
  • Table 160. Formycon Aflibercept Biosimilars Product
  • Table 161. Formycon Recent Development
  • Table 162. Aflibercept Biosimilars Market Trends
  • Table 163. Aflibercept Biosimilars Market Drivers
  • Table 164. Aflibercept Biosimilars Market Challenges
  • Table 165. Aflibercept Biosimilars Market Restraints
  • Table 166. Aflibercept Biosimilars Distributors List
  • Table 167. Aflibercept Biosimilars Downstream Customers
  • Table 168. Research Programs/Design for This Report
  • Table 169. Key Data Information from Secondary Sources
  • Table 170. Key Data Information from Primary Sources
  • Table 171. QYR Business Unit and Senior & Team Lead Analysts

List of Figures

  • Figure 1. Aflibercept Biosimilars Product Picture
  • Figure 2. Global Aflibercept Biosimilars Market Size, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 3. Global Aflibercept Biosimilars Market Size Status and Outlook (2018-2029) & (US$ Million)
  • Figure 4. Global Aflibercept Biosimilars Sales Status and Outlook (2018-2029) & (K Units)
  • Figure 5. Product Picture of 2mg
  • Figure 6. Global 2mg Sales YoY Growth (2018-2029) & (K Units)
  • Figure 7. Product Picture of 8mg
  • Figure 8. Global 8mg Sales YoY Growth (2018-2029) & (K Units)
  • Figure 9. Global Aflibercept Biosimilars Sales by Type (2018-2029) & (US$ Million)
  • Figure 10. Global Aflibercept Biosimilars Market Share by Type in 2023 & 2029
  • Figure 11. North America Aflibercept Biosimilars Sales Market Share in Volume by Type in 2023
  • Figure 12. North America Aflibercept Biosimilars Sales Market Share in Value by Type in 2023
  • Figure 13. Europe Aflibercept Biosimilars Sales Market Share in Volume by Type in 2023
  • Figure 14. Europe Aflibercept Biosimilars Sales Market Share in Value by Type in 2023
  • Figure 15. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Volume by Type in 2023
  • Figure 16. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Value by Type in 2023
  • Figure 17. Latin America Aflibercept Biosimilars Sales Market Share in Volume by Type in 2023
  • Figure 18. Latin America Aflibercept Biosimilars Sales Market Share in Value by Type in 2023
  • Figure 19. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Volume by Type in 2023
  • Figure 20. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Value by Type in 2023
  • Figure 21. The Largest Manufacturers in the World: Market Share by Aflibercept Biosimilars Sales in 2022
  • Figure 22. The 5 and 10 Largest Manufacturers in the World: Market Share by Aflibercept Biosimilars Revenue in 2022
  • Figure 23. Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
  • Figure 24. Product Picture of Hospitals
  • Figure 25. Global Hospitals Sales YoY Growth (2018-2029) & (K Units)
  • Figure 26. Product Picture of Clinics
  • Figure 27. Global Clinics Sales YoY Growth (2018-2029) & (K Units)
  • Figure 28. Product Picture of Others
  • Figure 29. Global Others Sales YoY Growth (2018-2029) & (K Units)
  • Figure 30. Global Aflibercept Biosimilars Sales by Application (2018-2029) & (US$ Million)
  • Figure 31. Global Aflibercept Biosimilars Market Share by Application in 2022 & 2029
  • Figure 32. North America Aflibercept Biosimilars Sales Market Share in Volume by Application in 2022
  • Figure 33. North America Aflibercept Biosimilars Sales Market Share in Value by Application in 2022
  • Figure 34. Europe Aflibercept Biosimilars Sales Market Share in Volume by Application in 2022
  • Figure 35. Europe Aflibercept Biosimilars Sales Market Share in Value by Application in 2022
  • Figure 36. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Volume by Application in 2022
  • Figure 37. Asia-Pacific Aflibercept Biosimilars Sales Market Share in Value by Application in 2022
  • Figure 38. Latin America Aflibercept Biosimilars Sales Market Share in Volume by Application in 2022
  • Figure 39. Latin America Aflibercept Biosimilars Sales Market Share in Value by Application in 2022
  • Figure 40. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Volume by Application in 2022
  • Figure 41. Middle East and Africa Aflibercept Biosimilars Sales Market Share in Value by Application in 2022
  • Figure 42. Aflibercept Biosimilars Industrial Chain Analysis
  • Figure 43. Channels of Distribution
  • Figure 44. Distributors Profiles
  • Figure 45. Bottom-up and Top-down Approaches for This Report
  • Figure 46. Data Triangulation
  • Figure 47. Key Executives Interviewed 115